Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.

British journal of haematology - 1 May 2015

Asvadi Parisa, Cuddihy Andrew, Dunn Rosanne D, Jiang Vivien, Wong Mae X, Jones Darren R, Khong Tiffany, Spencer Andrew

Abstract excerpt

MDX-1097 is an antibody specific for a unique B cell antigen called kappa myeloma antigen (KMA) that consists of cell membrane-associated free kappa light chain (κFLC). KMA was detected on kappa human multiple myeloma cell lines (κHMCLs), on plasma cells (PCs) from kappa multiple myeloma (κMM) patients and on κPC dyscrasia tissue cryosections. In primary κMM samples, KMA was present on CD38+ cells that were CD138...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody-Dependent Cell Cytotoxicity
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Immunoglobulin kappa-Chains

Share to Lenalidomide

Share to Multiple Myeloma

Share to Plasma Cells

Share to Thalidomide

Source

Identifiers

PMID: 25653020
DOI: 10.1111/bjh.13298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.PMID 25653020Read ↗

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myelomaSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.Semantic proximity Read ↗

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Semantic proximity Read ↗

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.Semantic proximity Read ↗

Multiple myeloma: lusting for NF-kappaB.Semantic proximity Read ↗

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple MyelomaSemantic proximity Read ↗

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class ISemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.